Soluble ST2 links inflammation to outcome after subarachnoid hemorrhage.
Case-Control Studies
Cerebrospinal Fluid
/ metabolism
Cross-Sectional Studies
Female
Genetic Predisposition to Disease
/ genetics
Humans
Inflammation
/ complications
Inflammation Mediators
/ metabolism
Interleukin-1 Receptor-Like 1 Protein
/ blood
Lipopolysaccharide Receptors
/ biosynthesis
Longitudinal Studies
Male
Middle Aged
Monocytes
/ metabolism
Outcome Assessment, Health Care
Receptors, IgG
/ biosynthesis
Subarachnoid Hemorrhage
/ complications
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
11
03
2019
revised:
08
07
2019
accepted:
08
07
2019
pubmed:
11
7
2019
medline:
14
4
2020
entrez:
11
7
2019
Statut:
ppublish
Résumé
To investigate whether soluble growth stimulation expressed gene 2 (sST2), a prognostic marker in cardiovascular and inflammatory disorders, is associated with neurological injury after aneurysmal subarachnoid hemorrhage (SAH). We studied SAH patients from 2 independent cohorts. Outcome assessments included functional status at 90 days using the modified Rankin Scale (mRS), mortality, and delayed cerebral ischemia (DCI). The relationships between sST2 plasma level and outcome measures were assessed in both cross-sectional and longitudinal analysis. Primary blood mononuclear cells from SAH patients and elective aneurysm controls were analyzed by multiparameter flow cytometry. In the discovery cohort, sST2 predicted 90-day mRS 3-6 (C index = 0.724, p < 0.001) and mortality in Kaplan-Meier analysis (p < 0.001). The association with functional status was independent of age, sex, World Federation of Neurosurgical Societies score, modified Fisher score, treatment modality, and cardiac comorbidities (adjusted odds ratio = 2.28, 95% confidence interval = 1.04-5.00, p = 0.039). Higher sST2 concentration was observed in those patients with DCI (90.8 vs 53.7ng/ml, p = 0.003). These associations were confirmed in a replication cohort. In patients with high sST2, flow cytometry identified decreased expression of CD14 (4.27 × 10 Plasma sST2 predicts DCI, functional outcome, and mortality after SAH, independent of clinical and radiographic markers. Elevated sST2 is also associated with changes in CD14
Identifiants
pubmed: 31291030
doi: 10.1002/ana.25545
pmc: PMC6727654
mid: NIHMS1048440
doi:
Substances chimiques
IL1RL1 protein, human
0
Inflammation Mediators
0
Interleukin-1 Receptor-Like 1 Protein
0
Lipopolysaccharide Receptors
0
Receptors, IgG
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
384-394Subventions
Organisme : American Heart Association
ID : 17CSA33550004
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS099209
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS076597
Pays : United States
Organisme : NINDS NIH HHS
ID : L30 NS097948
Pays : United States
Organisme : American Academy of Neurology
ID : AI18-0000000062
Pays : International
Informations de copyright
© 2019 American Neurological Association.
Références
Eur J Biochem. 1999 Sep;264(2):397-406
pubmed: 10491084
Stroke. 2001 Sep;32(9):1989-93
pubmed: 11546886
Circulation. 2003 Feb 11;107(5):721-6
pubmed: 12578875
J Allergy Clin Immunol. 2003 Mar;111(3):450-63; quiz 464
pubmed: 12642820
J Neurosurg. 2003 Jun;98(6):1222-6
pubmed: 12816268
Nat Immunol. 2004 Apr;5(4):373-9
pubmed: 15004556
Circulation. 2004 May 11;109(18):2186-90
pubmed: 15117853
Immunity. 2005 Nov;23(5):479-90
pubmed: 16286016
Neurosurgery. 2006 Jul;59(1):21-7; discussion 21-7
pubmed: 16823296
J Biol Chem. 2007 Sep 7;282(36):26369-80
pubmed: 17623648
Circulation. 2008 Apr 15;117(15):1936-44
pubmed: 18378613
J Neurosurg. 2008 Jul;109(1):38-43
pubmed: 18593272
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10913-8
pubmed: 18667700
Nat Rev Drug Discov. 2008 Oct;7(10):827-40
pubmed: 18827826
Circulation. 2008 Nov 4;118(19):2005-10
pubmed: 18981315
Tissue Antigens. 2009 Mar;73(3):206-12
pubmed: 19254249
Neuroradiology. 2009 Dec;51(12):813-9
pubmed: 19623472
Clin Chim Acta. 2009 Nov;409(1-2):33-40
pubmed: 19699192
Blood. 2009 Nov 12;114(20):4422-31
pubmed: 19762486
Stroke. 2010 Jan;41(1):e47-52
pubmed: 19875741
Clin Exp Immunol. 2010 Oct;162(1):1-11
pubmed: 20682002
Stroke. 2010 Oct;41(10):2391-5
pubmed: 20798370
Circ Heart Fail. 2011 Mar;4(2):180-7
pubmed: 21178018
J Cereb Blood Flow Metab. 2011 Jun;31(6):1443-51
pubmed: 21285966
Lancet Neurol. 2011 Jul;10(7):626-36
pubmed: 21641282
N Engl J Med. 2011 Dec 29;365(26):2463-72
pubmed: 22204723
J Neuroinflammation. 2012 Feb 08;9:28
pubmed: 22316109
Stroke. 2012 Jun;43(6):1711-37
pubmed: 22556195
Acta Neurochir Suppl. 2013;115:233-8
pubmed: 22890674
J Cereb Blood Flow Metab. 2013 Jul;33(7):1025-31
pubmed: 23512133
Cytometry A. 2013 Aug;83(8):702-13
pubmed: 23650273
Transl Stroke Res. 2013 Aug;4(4):432-46
pubmed: 23894255
Nat Rev Neurol. 2014 Jan;10(1):44-58
pubmed: 24323051
Biomed Res Int. 2014;2014:384342
pubmed: 25105123
Springerplus. 2015 Apr 23;4:195
pubmed: 25977890
Int J Mol Sci. 2016 Apr 02;17(4):497
pubmed: 27049383
J Neuroinflammation. 2016 Aug 30;13(1):217
pubmed: 27576738
World Neurosurg. 2017 May;101:666-676.e1
pubmed: 28323187
World Neurosurg. 2017 Aug;104:152-157
pubmed: 28512045
Front Immunol. 2017 Jul 24;8:892
pubmed: 28791027
Ann Clin Transl Neurol. 2017 Jul 05;4(8):553-563
pubmed: 28812045
World Neurosurg. 2017 Dec;108:206-215
pubmed: 28866066
J Neurosci. 2017 Oct 4;37(40):9614-9616
pubmed: 28978698
ACS Chem Neurosci. 2019 Jan 16;10(1):412-423
pubmed: 30117729
J Neurosurg. 1988 Jun;68(6):985-6
pubmed: 3131498
N Engl J Med. 1983 Mar 17;308(11):619-24
pubmed: 6338383
Cell Growth Differ. 1995 Feb;6(2):179-84
pubmed: 7756176
EMBO J. 1994 Mar 1;13(5):1176-88
pubmed: 8131748
J Exp Med. 1998 Mar 2;187(5):787-94
pubmed: 9480988
Acta Neurochir (Wien). 1998;140(9):943-51
pubmed: 9842432